Advertisement


Rogerio Lilenbaum, MD, on Metastatic NSCLC: Managing EGFR-Mutation–Positive Disease

2016 NCCN Annual Conference (1)

Advertisement

Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.



Related Videos

Multiple Myeloma

Kenneth Anderson, MD, on Multiple Myeloma Guideline Updates

Kenneth Anderson, MD, of Dana-Farber Cancer Institute, discusses how the many advances in the treatment of multiple myeloma affect current and future clinical practice.

Leukemia

Jeffrey Jones, MD, MPH, on Chronic Lymphocytic Leukemia: Optimizing Treatment With New Agents

Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.

Colorectal Cancer

Alan Venook, MD, on Metastatic Colorectal Cancer: Choosing Optimal Treatment Strategies

Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.

Hepatobiliary Cancer

Daniel T. Chang, MD, on Hepatocellular Carcinoma: Guideline Updates for Locoregional Treatment

Daniel T. Chang, MD, of the Stanford Cancer Institute, discusses the role of radiation therapy in the treatment of hepatocellular carcinoma.

Breast Cancer

Kevin C. Oeffinger, MD, on Controversies in Breast Cancer Screening Strategies

Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, discusses American Cancer Society recommendations, including the advice that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45, and that women 55 and older should have biennial screening.

Advertisement

Advertisement




Advertisement